Acute non-hemolytic transfusion reactions and HLA class I antibody: advantages of solid phase assay compared with conventional complement-dependent assay by Imoto, S et al.
Transfusion Medicine, 2010, 20, 95–103 doi: 10.1111/j.1365-3148.2009.00972.x
ORIGINAL ARTICLE
Acute non-hemolytic transfusion reactions and HLA class I
antibody: advantages of solid phase assay compared with
conventional complement-dependent assay
S. Imoto,1 K. Kawamura,1,2 Y. Tokumine,3 N. Araki,1 S. Akita,1 C. Nishimura,1,4 H. Inaba,1,5
K. Saigo,6 O. Mabuchi1 & H. Okazaki2 1Japanese Red Cross Hyogo Blood Center, Kobe, Japan, 2Japanese Red Cross Society,
Blood Service Headquarters, Central Blood Institute, Tokyo, Japan, 3Itami General Hospital, Itami, Japan, 4Japanese Red Cross Himeji Hospital,
Himeji, Japan, 5Japanese Red Cross Osaka Blood Center, Osaka, Japan, and 6Himeji Dokkyo University, Himeji, Japan
Received 2 February 2009; accepted for publication 6 September 2009
SUMMARY. To evaluate the speciﬁc reactivity of HLA
Class I antibodies (HLA-I Abs) in acute non-hemolytic
transfusion reactions (ANHTRs) using solid phase
assays (SPAs) and conventional complement-dependent
lymphocyte cytotoxicity test (LCT). ANHTRs are major
issues in transfusion medicine. Anti-leukocyte antibod-
ies have been implicated as one of the causative agents
of transfusion-related acute lung injury (TRALI) and
febrile reaction. Antibodies to HLA Class I and/or
Class II (HLA Abs) have been intensively studied using
SPAs for TRALI, but not for febrile reaction. About 107
patients and 186 donors associated with ANHTRs were
screened for HLA Abs by SPAs such as enzyme-linked
immunosorbent assay (ELISA) and the Luminex method.
When HLA-I Ab was detected, its speciﬁc reactivity was
evaluated by comparing its speciﬁcity identiﬁed by the
Luminex method using recombinant HLA molecules
and cognate HLA antigens (Ags), as well as LCT with
or without anti-human globulin (AHG). The incidences
of HLA Abs were as high as 32·7% of patients’ serum
samples and 16% of donors’ serum samples. The inci-
dence of HLA-I Abs did not differ signiﬁcantly between
cases of febrile and allergic reactions. However, HLA-I
Abs associated with febrile reaction showed a signif-
icantly higher rate of possessing speciﬁc reactivity to
cognate HLA Ags than those associated with allergic
reactions. In addition, the Luminex method enabled the
detection of HLA-I Abs much earlier than AHG-LCT
in serum samples from a patient with febrile reaction
and platelet transfusion refractoriness (PTR). SPAs seem
more useful than AHG-LCT for evaluating reactivity of
antibodies in ANHTR cases.
Key words: acute non-hemolytic transfusion reactions,
febrile reaction, HLA Class I antibodies, recombinant
HLA molecules, solid phase assays, TRALI.
After a marked decrease in the incidence of transfusion-
transmitted infectious events, acute non-hemolytic
transfusion reactions (ANHTRs) have become the
major issues (Combs et al., 2002; Klein & Anstee,
2005). ANHTRs range from mild urticaria, febrile
reaction to the most life-threatening transfusion-related
acute lung injury (TRALI) (Silliman et al., 2003;
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Bux 2005). Anti-leukocyte antibodies have been impli-
cated as one of the causative agents of TRALI and
febrile reaction (Thompson et al., 1971; Popovsky &
Moore, 1985; Payne R, 1957; de Rie et al., 1985).
Among anti-leukocyte antibodies, antibodies to human
leukocyte antigen (HLA) Class I and/or Class II
(HLA Abs) are much more frequently detected than
anti-granulocyte antibodies (Bux et al., 1992; Kopko
et al., 2003; Zupanska et al., 2007). Sensitive solid
phase assays (SPAs) using plastic plates [enzyme-
linked immunosorbent assay (ELISA)] or microbeads
(ﬂow cytometry or Luminex method) are commer-
cially available for HLA Abs (Stroncek et al., 2007).
For TRALI, HLA Abs have been intensively analyzed
using SPAs, but for febrile reaction, SPAs have not
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been used except in our previous study (Payne R, 1957;
Decary et al., 1984; de Rie et al., 1985; Imoto et al.,
2007). TRALI is frequently accompanied by fever. As
Davis et al. have recently reported in ‘a Touch of
TRALI’, some of the TRALI cases may have been
classiﬁed into febrile reaction when the pulmonary
manifestation was less severe (Davis et al., 2008). SPA-
based analysis of HLA Abs not only for TRALI, but
also for febrile reaction and allergic reactions may pro-
vide useful information for understanding the role of
HLA Abs.
Platelet transfusion refractoriness (PTR) is also an
important issue in transfusion medicine. HLA-I Abs in
patients’ sera have been implicated in most of the PTR
cases. For pateitns with PTR, screening of donor(s)
for HLA-compatible platelet concentrates (HLA-PCs)
is necessary as soon as possible.
We in a regional blood service center of the Japanese
Red Cross Society (JRCS) have studied ANHTRs
(Imoto et al., 2007). Moreover, we have promoted
the registration of donors for HLA-PCs. SPA-based
analyses gave us high HLA Abs positivity rates, 36%
in female patients’ sera and 13% in female donors’
sera associated with ANHTRs, whereas no signiﬁcant
difference was observed between allergic and febrile
reactions (Imoto et al., 2007). The results suggest that
most of the HLA Abs were coincidentally detected
but not causative. To evaluate the role of detected
HLA Abs, their speciﬁc reactivity to cognate HLA
Ags should be examined. In this study, by utilizing
the HLA-typing data of donors for HLA-PCs, we were
able to evaluate the speciﬁc reactivity of HLA-I Abs
detected in 16 serum samples associated with 12 cases
of ANHTRs. The speciﬁcity of the HLA-I Abs was
identiﬁed by the Luminex method using recombinant
HLA molecules, LABScreen® Single Antigen. The
speciﬁc reactivity of the HLA-I Abs to the cognate
HLA Ags was evaluated by comparing the speciﬁcity
of the antibodies and the cognate HLA -A and -B loci,
as well as by conventional AHG-LCT. We examined
only the speciﬁc reactivity of HLA-I Abs, because the
HLA-typing data of donors were for HLA-PCs; thus,
data only for HLA Class I loci were available. We also
present a PTR case with several episodes of febrile as
well as allergic reactions, for which we were able to
sequentially analyze HLA-I Abs.
MATERIALS AND METHODS
Patients, blood products and donors
From 12 March 2004 to 26 December 2005, 107 cases
of ANHTRs (56 males and 51 females) were vol-
untarily reported from 36 hospitals located in Hyogo
prefecture. ANHTRs in all of these cases occurred
within 24 h of transfusion. There were 65 cases of
allergic reactions (ranging from urticaria to anaphy-
lactic), 28 cases of febrile reaction and 14 cases of
TRALI/dyspnoea (dyspnoea or hypoxia not due to bron-
chospasm. See Imoto et al., 2007 for details). About
186 blood components were involved; 77 red blood cell
concentrates (RCCs: 400-mL-whole-blood-derived, 66;
200-mL-whole-blood-derived, 11), 57 platelet concen-
trates (PCs; all were single-donor-apheresis-derived)
and52 freshfrozenplasma (FFP:400-mL-whole-blood-
derived, 38; single-donor-apheresis-derived, 14). The
186 blood components were derived from 126 male
(61·2%) and 60 female (38·8%) donors.
For all the 107 patients, sera were obtained from the
physicians after obtaining their informed consent. For
131 of the 186 donors of blood products associated with
ANHTRs, serum samples were prepared from blood
products in segment tubes obtained from physicians.
Before antibody detection, a donor’s plasma sample
was deﬁbrinated by treating with thrombin and calcium
chloride (Araki et al., 1995).
Assay of HLA Abs
ELISA (Lambda Antigen Tray™ (LAT); One Lambda,
Inc., Canoga Park, CA, USA) was used from March
2004 to September 2004 and the Luminex method from
October 2004 to December 2005, in accordance with
the manufacturer’s instructions. For ELISA, LAT-M
was used for screening and when the reaction was posi-
tive, the speciﬁcity of the antibody was identiﬁed using
another panel antigen tray, LAT-1240. For donor–
patient pair analysis, the speciﬁcity was determined by
the Luminex method using LABScreen® Single Anti-
gen (One Lambda). For the Luminex method, after
incubation with color-coded beads (LABScreen PRA
Class I and Class II), ﬂuorescent emission from the
beads was detected and analyzed using a Luminex 100
IS System (Luminex Corporation, Austin, TX, USA).
The antibody speciﬁcity to HLA -A, and -B alleles was
determined using LABScreen® Single Antigen.
HLA allele typing
When HLA-I Ab was detected in a donor’s serum, HLA
typing of the patient was performed. Blood collected
into an EDTA-2Na-containing tube was obtained from
the physician after obtaining the patient’s informed
consent. DNA typing of the HLA -A, -B and -C loci
was performed by the PCR-SSOP-Luminex method
using Genosearch HLA -A, -B and -C (MBL, Nagoya,
Japan) with a Luminex 100™ IS ﬂuoroanalyzer (Itoh
et al., 2005), in accordance with the manufacturer’s
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instructions. Data on HLA-typing by the same method
were available for donors who had been registered for
HLA-PC donation.
Crossmatching with AHG-LCT
Peripheral blood lymphocytes (PBLs) were sepa-
rated by centrifugation of EDTA-2Na-anticoagulated
blood over a Ficoll-Conray gradient. For donors who
had been registered for HLA-PCs, lymphocytes were
frozen-stored, and were prepared by thawing before
use. Crossmatching between HLA-I Ab-positive sera
and cognate lymphocytes was carried out by LCT and
AHG-LCT as previously described (Araki et al., 1995).
Brieﬂy, lymphocytes were mixed with serum and incu-
bated for 30 min at 22
◦C. Rabbit complement (Class I
Complement; One Lambda) was added and the mixture
was incubated for 60 min at 22
◦C. After addition of
2% eosin, the percentage of damaged cells was evalu-
ated under a microscope. The decision of positivity was
made when more than 20% of the cells were stained
with eosin.
RESULTS
Incidence of HLA Abs in patients and donors
About 107 cases of ANHTRs consisting of 65 cases of
allergic reactions, 28 cases of febrile reaction and 14
cases of TRALI/dyspnoea were analyzed. HLA Abs
were detected in 35 (32·7%) patients, 10 of the 56
(17·9%) males and 25 of the 51 (49%) females. Of
the 10 antibody-positive male patients, 5 possessed
antibodies to HLA Classes I and II, four to Class I
and one to Class II. Of the 25 antibody-positive female
patients, 19 possessed antibodies to HLA Classes I and
II, 5 to Class I, and 1 to Class II. Taken together, 33
patients possessed HLA-I Abs. The positivity rates of
HLA-I Ab were 30·8% for allergic reactions, 39·2%
for febrile reactions and 21·4% for TRALI/dyspnoea.
The differences were statistically not signiﬁcant.
The 131 (93 males and 38 females) donors were
examined. HLA Abs were detected in 16% of the
donors (10·8% of males and 28·9% of females). Of
the 10 antibody-positive male donors, three possessed
antibodies to HLA Class I and II, 6 to Class I, and 1
to Class II. Of the 11 antibody-positive female donors,
3 possessed antibodies to HLA Classes I and II, 5 to
Class I, and 3 to Class II. Taken together, 17 donors
possessed HLA-I Abs.
In total, 47 ANHTR cases were associated with
HLA-I Abs either in patients’ or donors’ sera.
Evaluation of speciﬁc reactivity of HLA-I Abs
Among the 33 cases with HLA-I-Ab-positive patients,
HLA-typing data of the donors were available for
seven cases. Among the 13 ANHTR cases with 17
HLA-I-Ab-positive donors, we were able to examine
HLA-typing data of the patients for 9 cases. As a
result, the speciﬁc reactivity of the HLA-I Abs to
cognate HLA Ags was examined for 16 donor–patient
pairs of the 12 ANHTR cases, consisting of 7 allergic
reactions, 4 febrile reaction, and 1 suspected case of
TRALI (Tables 1 and 2). Cases 5 and 6 occurred in
the same female patient at different times. Case 10 was
a suspected case of TRALI. The patient was a 6-year-
old boy with congenital deformity of the right lung lobe
and transposition of great artery. During cardiovascular
surgery, he developed severe hypoxia 90 min after
starting transfusion. Cardiac failure was excluded.
Chest radiography showed pulmonary edema of the
left lung and atelectasis of the right lung owing to the
congenital deformity. Although the pulmonary oedema
was unilateral, TRALI was suspected clinically.
Speciﬁcity of HLA-I Abs identiﬁed using LAB-
Screen Single Antigen was compared with the cog-
nate HLA -A and -B loci (Table 2). For example, in
Case 3, the antibody in the patient’s serum showed
speciﬁcity to A11, B60 (*4001), B48, B45, B50, B81,
B41 and B49. The donor’s HLA type was A*2402/-,
B*0702/*4001 (B60), Cw4/7. As the antibody showed
speciﬁcity to one of the donor’s alleles, B60 (*4001),
the antibody was determined as having speciﬁc reac-
tivity. Speciﬁc reactivity was detected in seven cases,
consisting of two cases of allergic reactions, four cases
of febrile reaction, and one suspected case of TRALI.
For the suspected case of TRALI, 12 blood products
were transfused. HLA-I Abs were detected in three of
the 12 blood products. One of them showed speciﬁcity
to the patient’s HLA allele, B48, and was considered as
having speciﬁc reactivity. Results showed that 100% of
the cases of febrile reaction and the suspected case of
TRALI were associated with HLA -I Abs having spe-
ciﬁc reactivity, whereas only 28·6 %( 2 / 7 )o ft h ec a s e s
of allergic reactions were. The difference was statisti-
cally signiﬁcant (Fisher’s exact test, P = 0·0278).
The speciﬁc reactivity of HLA-I Abs was also tested
by lymphocyte crossmatching by AHG-LCT in 15 of
the 16 donor–patient pairs (Table 2). Case 5 was not
tested because of the poor viability of the donor’s
lymphocytes. Sera from only two of the 15 pairs
showed positive reactions, both of which showed
febrile reaction.
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Table 1. Characteristics of patients with ANHTRs
Patient’s Patient’s Type of transfusion Blood Donor’s
Case age gender Disease reaction component gender Leukoreduction*
1 68 Male Acute myeloid
leukemia
Allergic (skin
eruption)
RCC Female Yes bedside
2 48 Female NK cell lymphoma Allergic (skin
eruption)
PC Male Yes bedside
3 66 Female Acute myeloid
leukemia
Febrile (fever,
chills)
HLA-PC Male Yes bedside
4 31 Female Aplastic anemia Allergic (urticaria) HLA-PC Male Yes prestorage
5 27 Female Acute myeloid
leukemia
Febrile (fever) PC Male Yes prestorage
62 7 ∗ Female Acute myeloid
leukemia
Allergic (urticaria) HLA-PC Male Yes prestorage
7 67 Male Non-Hodgkin’s
lymphoma
Febrile (fever,
chills)
PC Female Yes prestorage
8 78 Male Acute myeloid
leukemia
Allergic (urticaria) PC Male Yes prestorage
9 58 Female Gastric cancer Allergic (urticaria) RCC Female no
10 6 Male Congenital
cardiovascular
anomaly
(transposition of
great artery,
deformity of the
right lung)
TRALI s/o (severe
hypoxia,
pulmonary
oedema,
mechanical
ventilation
required)
RCC 5 bags
FFP 6 bags
PC 1 bag
Male 7
Female 5
Yes bedside
no
Yes prestorage
11 68 Female Chronic
myelomonocytic
leukemia
Febrile (fever,
chills)
PC Male Yes prestorage
12 50 Male Gastric cancer Allergic (urticaria) PC Male Yes prestorage
∗Leukoreduction: Bedside indicates usage of leukoreduction ﬁlter at bedside. Prestorage indicates leukoreduction at blood center.
Sequential measurement of HLA-I Ab in a patient with
ANHTRs and PTR
Cases 5 and 6 occurred in the same patient at different
times (Tables 1 and 2). The patient was a 27-year-old
female with acute myeloid leukemia. She had two his-
tories of pregnancy. During her clinical course, she
developed fever and skin eruption after PC transfu-
sions, and also developed PTR (Fig. 1).
HLA-I Ab was sequentially measured using the
Luminex method (Fig. 2). HLA-I Ab was already
detected using LABScreen PRA in a serum sample
collected on March 17, before the ﬁrst transfusion.
Antibody speciﬁcity was measured using LABScreen
Single Antigen (Fig. 2E–H). The ﬁrst febrile reaction
occurred on April 19. Corrected count increment (CCI)
was less than 1000, indicating PTR (Fig. 1, Case
5 in Table 1). The donor’s HLA type was A24/31,
B35/54, Cw14/15 and serum collected on April 17
showed speciﬁcity to B54, one of the donor’s HLA
alleles, showing speciﬁc reactivity (Case 5 in Table 2).
The second febrile reaction occurred on May 27,
accompanied by skin eruption. The antibody showed
increased reaction intensity and reaction range, and
the serum sample collected on May 30 showed the
highest reaction intensity with the widest reaction range
(Fig. 2A–C).
After May 30, HLA-PC was transfused every time,
and thereafter, she did not suffer from febrile reac-
tion. The antibody in the serum samples collected
on July 1 showed a lower reaction intensity and nar-
rower reaction range (Fig. 2D). However, she devel-
oped skin eruption on July 1 after HLA-PC transfusion
(Case 6 in Tables 1 and 2, Fig. 1). Platelet recovery
was normal (CCI at 1 h was 12,750). The antibody
showed no speciﬁcity to the corresponding donor’s
HLA alleles (Table 2 and Fig. 2H), suggesting that the
antibody was not the causative agent of the allergic
reaction.
When the patient’s sera were tested by AHG-LCT
using panel lymphocytes, serum samples collected on
May 30 showed positive reactions, but serum samples
collected on March 17 showed negative reactions.
© 2009 The Authors
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ANHTR - --- - - -- - +  - - +  -- + ----
fever fever
&
skin eruption skin eruption
C C I                             <0 <1,000 12,750
PC      VV 
VV 
 V     V V V V V V V V V
HLA-PC                                                   V  VVVV
RCC     V          V V V V V
date     19 2123    10 1314 1617 192122   27 28 29    1  3 5 7 9       
March      April                    May         July
Fig. 1. Clinical course of patient with ANHTRs and PTR. Timing of transfusions of PC, HLA-PC and RCC is shown. ‘V’ in the
ﬁgure indicates transfusion of one blood component, ‘−’ indicates transfusion without ANHTRs and “+” indicates occurrence of
ANHTRs. The type of ANHTR is shown under the mark.
Serum samples collected on April 17 showed non-
speciﬁc reactions.
DISCUSSION
Using ELISA and the Luminex method, we observed
high incidences of HLA antibodies in both patients
and donors associated with ANHTRs. HLA Abs were
detected in 32·7% (49% of females and 17·9% of
males) of the patients’ serum samples and in 16%
(28·9% of females and 10·8% of males) of the donors’
serum samples. HLA-I Abs were positive in 30·8% of
the patients’ sera. Other investigators have reported
similar results (Fadeyi et al., 2008; Powers et al.,
2008). Powers and co-workers screened sera from
donors to the hospital blood bank by LABScreen
mixed assay, and detected HLA Abs among 42·5%
(211/497) of female donors with a history of pregnancy
and 12·0% (3/25) of male donors with a history of
transfusion (Powers et al., 2008). Densmore and co-
workers reported a lower percentage probably because
of a lower sensitivity of their assay method, AHG-LCT
(Densmore et al. 1999).
In our present study, the positivity rates of HLA-I Ab
in febrile reaction and allergic reactions were 39·2a n d
30·8%, respectively. The difference was statistically
not signiﬁcant. However, the rate of positive speciﬁc
reactivity of the HLA-I Abs which was determined by
comparing the speciﬁcity of HLA-I Ab and the cognate
HLA -A and -B loci, was signiﬁcantly higher in febrile
reaction (100%) than in allergic reactions (28·6%). In
contrast, crossmatching by AHG-LCT showed positive
reactions only in 13·3% of ANHTRs. Our results show
that HLA-I Abs detected in febrile reaction are more
often causative than those detected in allergic reactions,
and that SPAs were more sensitive than AHG-LCT.
Evaluation of the speciﬁc reactivity of HLA Abs by
comparing the antibody’s speciﬁcity and the cognate
HLA loci instead of LCT has been increasingly utilized
in the ﬁeld of organ transplantations (Pei et al., 2003;
Vaidya et al., 2006; Gupta et al., 2008), as well as
in unrelated cord blood transplantations (Takanashi
et al., 2008).
Regarding TRALI, we were able to evaluate only
one suspected case. HLA-I Abs were detected in 3 of
the 12 blood components, one of which showed speci-
ﬁcity to the patient’s HLA Ag, whereas crossmatching
by AHG-LCT showed negative results. Identiﬁcation
of the donor implicated in TRALI seems important to
prevent further occurrence of TRALI (Kleinman et al.,
2004; Eder et al., 2007; Stroneck & Klein 2007). Our
result shows that SPA-based evaluation of speciﬁc reac-
tivity of HLA-I Abs is better than AHG-LCT to identify
the implicated donors in suspected cases of TRALI.
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Fig. 2. HLA-I Abs measured using LABScreen PRA and Single Antigen. The serum samples from the patient with acute
myeloid leukemia collected at four time points were analyzed using LABScreen PRA (A, B, C, D) to examine the range and
intensity of reactivity and using LABScreen Single Antigen (E, F, G, H) to determine antibody speciﬁcity. Microbeads coated
with HLA Class I molecules were laterally allocated in order of reaction intensity. In graphs A–D, the uppermost line indicates
‘very strong positive cutoff’, the second line ‘strong positive cutoff’, the third line ‘positive cutoff’, the fourth line ‘weak positive
cutoff’, as indicated in Fig. 2A. In graphs E–H, the upper line indicates ‘strong positive cutoff’, the middle line ‘weak positive
cutoff’, the lower line ‘gray cutoff’, as indicated in Fig. 2E.
For a PTR case, we were able to sequentially analyze
HLA-I Ab. HLA-I Ab was detected by LABScreen
PRA much earlier than by AHG-LCT. This case
demonstrates the relationship between the speciﬁc
reactivity of HLA-I Ab and the occurrence of febrile
reaction. In addition, data on antibody speciﬁcity
seemed useful for selection of HLA-PC donors. Sato
and co-workers reported the cases of two PTR patients
whose anti-HLA-I Abs were detected by FlowPRA but
not by AHG-LCT (Sato et al., 2005). The patients were
able to obtain HLA-PCs much earlier than expected by
AHG-LCT. Although AHG-LCT has been used as a
standard assay method to select donors for HLA-PC,
SPA-based methods seem to be more beneﬁcial.
© 2009 The Authors
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In summary, using SPA-based methods, we were
able to observe a signiﬁcantly higher rate of positive
speciﬁc reactivity of HLA-I Abs in febrile reaction than
in allergic reactions. SPA-based methods seem to be
more beneﬁcial than AHG-LCT to identify implicated
donors in suspected cases of TRALI, and for select-
ing compatible HLA-PC donors for patients with PTR.
However, the number of evaluated cases was small,
and we were not able to evaluate the speciﬁc reac-
tivity of co-existing HLA Class II Abs, whereas we
conﬁrmed the negativity for anti-granulocyte antibod-
ies examined by previously described methods (Imoto
et al., 2007). Further investigation is necessary to con-
ﬁrm our conclusion.
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